

[Amikacin](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.5. Antituberculosis medicines](#)

ATC codes: [J01GB06](#)

EMLc

Indication

Multi-drug resistant Mycobacterium tuberculosis ICD11 code: [ML32.00](#)

INN

Amikacin

Medicine type

Chemical agent

Antibiotic groups

[ACCESS](#)

List type

Core

Additional notes

Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.

Formulations

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

EML status history

First added in 1999 ([TRS 895](#))

Changed in 2007 ([TRS 950](#))

Changed in 2009 ([TRS 958](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2023 ([TRS 1049](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Amikacin](#)

DrugBank

[Amikacin](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc.